The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL).
 
Nirav Niranjan Shah
Stock and Other Ownership Interests - Tundra Targeted Therapeutics
Consulting or Advisory Role - Incyte; Janssen Oncology; Juno/Bristol-Myers Sqibb; Kite, a Gilead company; Loxo/Lilly; Novartis; Seagen; TG Therapeutics
Research Funding - Adaptive Biotechnologies; Loxo/Lilly; Miltenyi Biotec
Travel, Accommodations, Expenses - Miltenyi Biotec
 
Aniko Szabo
No Relationships to Disclose
 
Saurabh Rajguru
No Relationships to Disclose
 
Sumana Devata
Stock and Other Ownership Interests - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Novo Nordisk; Pfizer
Research Funding - Amgen
 
Mitch Howard
No Relationships to Disclose
 
Deepa Pereira
No Relationships to Disclose
 
Mariah Endres
No Relationships to Disclose
 
Walter L. Longo
No Relationships to Disclose
 
Mehdi Hamadani
Honoraria - Celgene
Consulting or Advisory Role - Abbvie; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Caribou Biosciences; crispr therapeutics; Gamida Cell; Genentech; Genmab; Incyte; Kite/Gilead; MorphoSys; Myeloid Therapeutics; Novartis; Omeros; Puma Biotechnology (I); Sanofi; Seagen; Verastem
Speakers' Bureau - ADC Therapeutics; AstraZeneca; BeiGene; Genzyme; Kite/Gilead
Research Funding - Astellas Pharma; Genzyme; Genzyme; Otsuka; Spectrum Pharmaceuticals; Takeda
 
Timothy S. Fenske
Stock and Other Ownership Interests - Merck
Honoraria - Adaptive Biotechnologies; ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; CSL Limited; Karyopharm Therapeutics; Kite, a Gilead company; MorphoSys; Pharmacyclics; Sanofi; Seagen; SERVIER; TG Therapeutics
Consulting or Advisory Role - Adaptive Biotechnologies; ADC Therapeutics; BeiGene; Bristol-Myers Squibb/Celgene; CSL Limited; Karyopharm Therapeutics; MorphoSys; Pharmacyclics; Seagen; SERVIER; TG Therapeutics
Speakers' Bureau - AstraZeneca; BeiGene; Kite, a Gilead company; Sanofi; Seagen; TG Therapeutics
Expert Testimony - Bayer
Travel, Accommodations, Expenses - AstraZeneca; Kite, a Gilead company; Sanofi; Seagen; TG Therapeutics
 
Christopher David Fletcher
No Relationships to Disclose